Table 5– Serious adverse events occurring in more than one macitentan-treated subject
Macitentan 10 mgPlacebo
Subjects11959
IPF worsening10 (8.4)6 (10.2)
Pneumonia6 (5.0)2 (3.4)
Respiratory failure4 (3.4)2 (3.4)
Hypoxia3 (2.5)2 (3.4)
Acute respiratory failure2 (1.7)1 (1.7)
Thrombocytopenia2 (1.7)0 (0.0)
  • Data are presented as n or n (%). Data are from subjects in the all-randomised set. IPF: idiopathic pulmonary fibrosis.